Tumor Genomic Profiling denied as non-formulary by Avalon Healthcare Solutions?

Avalon manages genetic/molecular testing UM for many BCBS plans. Tumor profiling per NCCN biomarker recommendations.

Confirm Avalon network status — reroute to in-network lab if denial is purely contractual. NCCN biomarker testing recommendations require panel-based testing (NSCLC: EGFR/ALK/ROS1/BRAF/KRAS/MET/RET/NTRK/ERBB2/PD-L1). ACOG #226 (2020) — cfDNA offered to all pregnancies.

## Why Avalon Healthcare Solutions Denied Tumor Genomic Profiling as "Non-Formulary" — and How to Appeal

A "non-formulary" denial for tumor genomic profiling (CGP) is unusual because CGP is typically managed as a diagnostic service or laboratory benefit rather than a drug formulary item — but Avalon Healthcare Solutions administers specialty and genomic benefits for many plans using their own coverage tiers, and some plans categorize specific genomic tests or laboratory panels in covered/non-covered tiers analogous to a formulary. This denial means the specific test ordered is not on Avalon's covered test list, or the ordering laboratory is not an in-network or approved vendor for this service.

## Why This Denial Is Frequently Appealable

Non-formulary or non-covered-vendor denials for diagnostic tests can often be resolved in one of two ways: (1) a formulary exception based on medical necessity — demonstrating that no covered equivalent test provides the same clinical information; or (2) a network adequacy argument — demonstrating that no in-network laboratory can perform the ordered test at the required clinical specification. Understanding which issue applies to your denial determines which argument to lead with.

## Federal Appeal Framework

Under ACA Section 2719, you have the right to an internal appeal and independent external review. ERISA Section 503 applies to employer-sponsored plans. External review must generally be requested within approximately four months of a final internal denial. For active oncology cases, request expedited review, which is typically decided within 72 hours.

## What to Gather Before You Appeal

• Avalon's covered test list or genomic benefit policy. Identify exactly what tests are covered and why the ordered test falls outside coverage. Ask Avalon directly (in writing) what covered alternative test, if any, they consider equivalent.
• Treating oncologist's letter addressing equivalency. The oncologist should explain why no covered-tier test provides the same clinical information as the ordered test for this patient's specific cancer type, stage, and clinical question. If Avalon proposes an alternative test, the oncologist should address why it is clinically inadequate.
• Laboratory documentation. If the issue is a non-participating laboratory, document whether any in-network laboratory offers a test with equivalent clinical capabilities. If no equivalent in-network option exists, you have a network adequacy argument.
• Diagnosis, staging, and clinical context. Confirm tumor type, stage, and the specific clinical question the test is meant to answer — this grounds the medical-necessity overlay on the non-formulary denial.

## Criteria-Mapping Structure

| Denial basis | Your response | Document | |---|---|---| | Test not on covered list | No covered equivalent provides same information | Oncologist letter | | Non-participating lab | No in-network lab offers equivalent test | Lab network search + letter | | Clinical need for specific test | Treatment-selection rationale | Oncologist letter + chart |

## Practical Advice

Always ask Avalon in writing: "What specific covered test do you consider equivalent, and what is the clinical basis for that equivalency determination?" Their answer — or refusal to answer — becomes part of your appeal record. Non-formulary exceptions for diagnostics are routinely granted when the prescribing physician establishes that no covered alternative meets the patient's clinical need.